| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/11/2004 | CA2062341C Use of hydrophilic penetrating agents in dermatological compositions for the treatment of onychomycosis, and corresponding compositions |
| 05/08/2004 | WO2004064828A1 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
| 05/06/2004 | WO2004037983A2 Caged ligands and uses thereof |
| 05/06/2004 | WO2004037865A1 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
| 05/06/2004 | WO2004037341A2 Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
| 05/06/2004 | WO2004037316A2 Nanoparticle delivery system |
| 05/06/2004 | WO2004037314A2 Patch and kit containing delayed-type hypersensitivity inducer |
| 05/06/2004 | WO2004037292A1 Colon cleansing compositions |
| 05/06/2004 | WO2004037291A1 Pharmaceutical product for endonasal administration for treating central nervous system diseases and disorders |
| 05/06/2004 | WO2004037290A1 Sustained release composition for oral administration of drugs |
| 05/06/2004 | WO2004037289A2 Novel injectable depot formulations |
| 05/06/2004 | WO2004037288A1 Agent eleveting dendritic cell precursor level in blood |
| 05/06/2004 | WO2004037282A1 The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| 05/06/2004 | WO2004037280A1 Angiogenesis inducer |
| 05/06/2004 | WO2004037275A1 Bile acid conjugates and particles formed therewith |
| 05/06/2004 | WO2004037267A1 Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
| 05/06/2004 | WO2004037229A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 05/06/2004 | WO2004037224A1 Depot formulations of arylheterocyclic active agents in the form of a suspension |
| 05/06/2004 | WO2004037208A2 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| 05/06/2004 | WO2004037197A2 Antifungal formulations |
| 05/06/2004 | WO2004037187A2 Metal-containing materials, compositions and methods |
| 05/06/2004 | WO2004037184A2 Methods for the treatment of skin disorders |
| 05/06/2004 | WO2004037173A2 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | WO2004017895A3 Formaldehyde-ammonium salt complexes for the stabilization of blood cells |
| 05/06/2004 | WO2004009135A3 Conjugates of biocompatible polymers with nuclide activation therapy reagents |
| 05/06/2004 | WO2003104254A3 Novel derivatives of androstane and androstene with ascorbic a cid and use thereof in treating or preventing various conditions, diseases, and disorders |
| 05/06/2004 | WO2003103389A3 Cryopreservation of haptenized tumor cells |
| 05/06/2004 | WO2003092580A3 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 05/06/2004 | WO2003088923A3 Methods of treating ileus |
| 05/06/2004 | WO2003086470A3 Smac-peptides as therapeutics against cancer and autoimmune diseases |
| 05/06/2004 | WO2003051304A3 Bioadhesive drug delivery system with enhanced gastric retention |
| 05/06/2004 | WO2003050502A9 Prospective identification and characterization of breast cancer stem cells |
| 05/06/2004 | WO2003027148A8 Disulfide-reduced neogalactosyl serum albumin and use of radiolabeled derivative thereof for liver imaging |
| 05/06/2004 | WO2003026625A9 Modified release dosage forms |
| 05/06/2004 | WO2003026624A9 Modified release dosage forms |
| 05/06/2004 | WO2003020219B1 Aerosolized decongestants for the treatment of sinusitis |
| 05/06/2004 | WO2003009817A9 Stable lyophilized pharmaceutical formulation of igg antibodies |
| 05/06/2004 | WO2002087510A3 Subcellular targeting of therapeutic proteins |
| 05/06/2004 | WO2002056881A8 Fenofibrate tablets |
| 05/06/2004 | US20040087669 Homogenizing starch and swelling agents; extrusion using rotary dies |
| 05/06/2004 | US20040087666 Multilayer crystal structure containing guest molecule; encapsulation of a fluid; transferring; supplying hydrogen, methane as fuel |
| 05/06/2004 | US20040087664 Immobilization of a drug to carotenoid; eye diseases, antiinflammatory agents |
| 05/06/2004 | US20040087649 Cytotoxic agents comprising taxanes and their therapeutic use |
| 05/06/2004 | US20040087602 Topical viricide; photostabilizer for inorganic oxide pigment; 2-bromovinyl deoxyuridine mixtures |
| 05/06/2004 | US20040087578 Pharmaceutical compositions containing carvedilol and hydrochlorothiazide |
| 05/06/2004 | US20040087567 Anticancer agents; particularly liver cancer |
| 05/06/2004 | US20040087550 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| 05/06/2004 | US20040087544 .1-10,000 mg/mL of a glycosaminoglycan, .001-5% of osmolarity-correcting agent, .0001-30% of a preservative of paraben, benzyl alchool, chlorbutanol, chlorcresol, benzetoin chloride, benzalconium chloride and solvents; ph 4.5-8.5 |
| 05/06/2004 | US20040087538 Nucleic acids containing unmethylated cytosine-guanine dinucleotides activate lymphocytes and redirect an immune response from th2 to th1 |
| 05/06/2004 | US20040087529 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 05/06/2004 | US20040087524 Agent for postoperative use after removal of bone tumours |
| 05/06/2004 | US20040087520 Compositions and methods for delivery of therapeutic agents |
| 05/06/2004 | US20040087517 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| 05/06/2004 | US20040087510 Cardiovascular diseases and disorders; sustained delivery of nitric oxide |
| 05/06/2004 | US20040087507 Containing amino acid; long term storage stability |
| 05/06/2004 | US20040087501 Conjugates of defined stoichiometry |
| 05/06/2004 | US20040087497 CD10-activated prodrug compounds |
| 05/06/2004 | US20040087494 Glycopeptide carboxy-saccharide derivatives |
| 05/06/2004 | US20040087488 Hydrophilic biopolymer-drug conjugates, their preparation and use |
| 05/06/2004 | US20040087486 Inhibiting vascular occlusive events; reducing circulating count below normal levels without serious adverse consequence |
| 05/06/2004 | US20040087483 Iodothyronine compositions |
| 05/06/2004 | US20040087482 Microparticle-drug conjugates for biological targeting |
| 05/06/2004 | US20040087035 Using myeloproliferative leukemic inhibitory agents to treatment and/ or prevention platelet related thrombotic and vaso-occlusive disorder |
| 05/06/2004 | US20040087024 Comprises polyethylenimine coupled to cyclodextrins; for cell transfection; kits |
| 05/06/2004 | US20040087015 Polysaccharides; antidiabetic agents; Parkinson's disease |
| 05/06/2004 | US20040086992 Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| 05/06/2004 | US20040086991 Gels; immobilization of proteins; drug delivery |
| 05/06/2004 | US20040086977 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| 05/06/2004 | US20040086976 Genetically engineered erythropoietin for diagnosis, prevention and treatment of thrombis, cancer, neovascularization, inflammation and autoimmune diseases |
| 05/06/2004 | US20040086574 Iron-free multi-vitamin/mineral/antioxidant formulation, designed to optimize health and wellness, minimize oxidative stress, and normalize homocysteine levels |
| 05/06/2004 | US20040086571 For therapy of dyslipidemia and dyslipoproteinemia |
| 05/06/2004 | US20040086565 Orally administering to once prior to sleep a dosage formulation comprising a biologically inert pellet having a drug layer, an outer rate controlling layer |
| 05/06/2004 | US20040086562 Orally administering to a patient a spaced drug delivery system, wherein first therapeutically active agent is released immediately and second therapeutically active agent is released as a pulse at predetermined time after administration |
| 05/06/2004 | US20040086557 Polyethylene glycol coated Pokeweed Mitogen and Recombinant Interleukin II |
| 05/06/2004 | US20040086556 Transdermal and topical administration of local anesthetic agents using basic enhancers |
| 05/06/2004 | US20040086552 Transdermal therapeutic system for highly dispersed silicon dioxide |
| 05/06/2004 | US20040086548 Shape-retentive hydrogel particle aggregates and their uses |
| 05/06/2004 | US20040086546 Breath freshening and oral cleansing product with cinnamaldehyde |
| 05/06/2004 | US20040086517 Porous, implantable device containing a fibrous support and at least one antigen |
| 05/06/2004 | US20040086515 Modified in such a way that its half-life in the vascular compartment is prolonged |
| 05/06/2004 | US20040086514 Based on the finding of a specific Helicobacter pylori receptor in the human gastric epithelium; a glycolipid, lactotetraosylceramide, exclusively found in the human gastrointestinal tract |
| 05/06/2004 | US20040086486 Method of enhancing delivery of a therapeutic nucleic acid |
| 05/06/2004 | US20040086479 Can be chemically modified for different biomedical applications such as tissue engineering applications, wound management, contrast agents vehicles, drug delivery vehicles, etc. |
| 05/06/2004 | US20040086470 Stabilize oil-containing cosmetic preparations irrespective of the particle size of the pearlizing concentrates and without addition of polymers or inorganic carriers and hence would avoid separation |
| 05/06/2004 | US20040086465 Aerosol suspension formulations which are free of chlorofluorocarbons comprising mometasone furoate, a dry powder surfactant and HFA 227, |
| 05/06/2004 | US20040086462 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086461 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086459 Efficient for back scattering ultrasound energy |
| 05/06/2004 | US20040086458 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086457 Orally ingestible baked radiopaque product having a dry food texture |
| 05/06/2004 | EP1415998A2 Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| 05/06/2004 | EP1415669A1 Process for sterilization of protein containing biological compositions |
| 05/06/2004 | EP1415663A1 Sustained release hgf hydrogel preparations |
| 05/06/2004 | EP1415654A1 Enhancedly-solubilized beta-hydroxy acids and higher potency skin peels formulated therefrom |
| 05/06/2004 | EP1415649A1 Transdermal therapeutic system comprising oxybutynin |
| 05/06/2004 | EP1414989A1 Organometallic probe |
| 05/06/2004 | EP1414792A1 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates |
| 05/06/2004 | EP1414784A2 Amphiphilic star-like macromolecules for drug delivery |
| 05/06/2004 | EP1414498A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 05/06/2004 | EP1414497A1 Novel microemulsion and micelle systems for solubilizing drugs |